OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of first‐line treatments for patients with advanced anaplastic lymphoma kinase mutated, non–small cell cancer: A systematic review and network meta‐analysis
Peng Yang, Qiang Zhao, Ziyi Liao, et al.
Cancer (2023) Vol. 129, Iss. 8, pp. 1261-1275
Open Access | Times Cited: 11
Peng Yang, Qiang Zhao, Ziyi Liao, et al.
Cancer (2023) Vol. 129, Iss. 8, pp. 1261-1275
Open Access | Times Cited: 11
Showing 11 citing articles:
From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC
Sai‐Hong Ignatius Ou, Alexandria TM Lee, Misako Nagasaka
Critical Reviews in Oncology/Hematology (2023) Vol. 187, pp. 104019-104019
Open Access | Times Cited: 16
Sai‐Hong Ignatius Ou, Alexandria TM Lee, Misako Nagasaka
Critical Reviews in Oncology/Hematology (2023) Vol. 187, pp. 104019-104019
Open Access | Times Cited: 16
Case report: Alectinib-associated intestinal ulceration and colitis in a patient with non-small cell lung cancer and effective treatment with Mesalazine
Zijian Qiu, Ke Fei, Xiaoping Zhu
Pathology & Oncology Research (2025) Vol. 31
Open Access
Zijian Qiu, Ke Fei, Xiaoping Zhu
Pathology & Oncology Research (2025) Vol. 31
Open Access
Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis
Jinhe Xu, Wenting Zhang, Feilai Xie, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Jinhe Xu, Wenting Zhang, Feilai Xie, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Safety of Lorlatinib in ALK-Positive Non-Small-Cell Lung Cancer and Management of Central Nervous System Adverse Events
Saadettin Kılıçkap, Sertaç Ak, Oldac Uras Dursun, et al.
Future Oncology (2023) Vol. 19, Iss. 29, pp. 2003-2012
Open Access | Times Cited: 6
Saadettin Kılıçkap, Sertaç Ak, Oldac Uras Dursun, et al.
Future Oncology (2023) Vol. 19, Iss. 29, pp. 2003-2012
Open Access | Times Cited: 6
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
Laura Fabbri, Alessandro Di Federico, Martina Astore, et al.
Diagnostics (2023) Vol. 14, Iss. 1, pp. 48-48
Open Access | Times Cited: 6
Laura Fabbri, Alessandro Di Federico, Martina Astore, et al.
Diagnostics (2023) Vol. 14, Iss. 1, pp. 48-48
Open Access | Times Cited: 6
Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center
Ao Zeng, Yicheng Xiong, Jing Zhang, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 1, pp. 16-33
Open Access | Times Cited: 1
Ao Zeng, Yicheng Xiong, Jing Zhang, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 1, pp. 16-33
Open Access | Times Cited: 1
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-Addicted Non-Small Cell Lung Cancer: a systematic review and sensitivity-analysis.
Luca Mastrantoni, Giulia Giordano, Emanuele Vita, et al.
Cancer Treatment and Research Communications (2024) Vol. 41, pp. 100842-100842
Open Access | Times Cited: 1
Luca Mastrantoni, Giulia Giordano, Emanuele Vita, et al.
Cancer Treatment and Research Communications (2024) Vol. 41, pp. 100842-100842
Open Access | Times Cited: 1
Metastatic brain tumors: from development to cutting‐edge treatment
Guilong Tanzhu, Liu Chen, Jiaoyang Ning, et al.
MedComm (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Guilong Tanzhu, Liu Chen, Jiaoyang Ning, et al.
MedComm (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Comparative efficacy of targeted therapies and immunotherapy in advanced non-small cell lung cancer: a systematic review
Byron Cristobal Llongo Cali, Jorge Eduardo Paredes Jaramillo, Jennifer Alicia Álvarez Navas, et al.
International Journal of Research in Medical Sciences (2024) Vol. 12, Iss. 9, pp. 3384-3393
Open Access
Byron Cristobal Llongo Cali, Jorge Eduardo Paredes Jaramillo, Jennifer Alicia Álvarez Navas, et al.
International Journal of Research in Medical Sciences (2024) Vol. 12, Iss. 9, pp. 3384-3393
Open Access
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis
Xing Zhang, Jianbo Tong, Tianhao Wang, et al.
Computers in Biology and Medicine (2023) Vol. 169, pp. 107815-107815
Closed Access | Times Cited: 1
Xing Zhang, Jianbo Tong, Tianhao Wang, et al.
Computers in Biology and Medicine (2023) Vol. 169, pp. 107815-107815
Closed Access | Times Cited: 1
First-line treatment option for patients with ALK-positive metastatic NSCLC
А. L. Kornietskaya, Л. В. Болотина, S. F. Evdokimova, et al.
Meditsinskiy sovet = Medical Council (2023), Iss. 22, pp. 74-79
Open Access
А. L. Kornietskaya, Л. В. Болотина, S. F. Evdokimova, et al.
Meditsinskiy sovet = Medical Council (2023), Iss. 22, pp. 74-79
Open Access
